Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

NCT: NCT03311451 · ACTIVE_NOT_RECRUITING

NCT IDNCT03311451
StatusACTIVE_NOT_RECRUITING
Start Date2023-01-16
Completion2026-12-18

Brief Summary

The primary objective is to determine the safety and efficacy of the C2 CryoBalloon 180 Ablation System ("CryoBalloon 180") used at decreasing doses in ablation naïve patients with low- or high-grade dysplastic Barrett's Esophagus (BE) or with residual BE after resection of dysplasia or early adenocarcinoma.

Frequently Asked Questions

What is C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.?

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study. is a clinical trial registered under NCT03311451. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT03311451?

The current status of NCT03311451 (C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.) is: ACTIVE_NOT_RECRUITING.

When did C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study. start?

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study. started on 2023-01-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑